This study is testing an investigational drug called GB-0895 to see if it can help adults and adolescents (ages 12 to 80) with severe asthma that isn't well-controlled by their current medications. You would receive either GB-0895 or a placebo (an inactive substance) every six months for 52 weeks. The main goal is to see if GB-0895 can reduce the number of asthma attacks (exacerbations) you experience over one year. To join, you must have had asthma for at least two years and be on specific asthma controller medications. The study plans to include about 786 participants globally, but its current recruitment status is unclear.

Study design

This is a global, multi-center, randomized, double-blind, placebo-controlled Phase 3 study involving approximately 786 participants.

What's involved

You would receive study treatment every 6 months for 52 weeks, with visits every 1-2 months after the first month.

Compensation

Not stated in the trial record.

Follow-up

Participants are followed for 90 weeks, or up to 142 weeks if they join the optional open-label extension.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.